Biogen’s Aducanumab: One Positive Phase III Trial Is Good Enough For Demonstrating Efficacy, US FDA Says

 
• By Sue Sutter

Negative results from the Phase III ENGAGE trial – which may have been influenced by imbalance in ‘rapid progressors’ and differential effects of dosing protocol changes – do not negate persuasiveness of positive results from the EMERGE study, agency says in advisory committee briefing document; statistical reviewers dissent, call for a new trial of the Alzheimer's drug.

New life idea concept with seedling growing sprout (tree)
US FDA believes the Phase III EMERGE trial can stand on its own as pivotal efficacy evidence for aducanumab. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers